MEB Receives 86 Millions In Swedish Grants

Congratulations to the researchers at the Department of Medical Epidemiology and Biostatistics (MEB) who received a total of nearly 86 million SEK from the Swedish funding agencies (FORTE, the Swedish Research Council, the Swedish Cancer Society and the Erling-Persson Foundation)!

Project grants from the Swedish Cancer Society

Hans-Olov Adami

Project title: Microbiome, infection, inflammation and cancer risk.

Amount granted for 2025-2026: SEK 1 600 000

Mark Clements

Project title: Long-term effectiveness and costeffectiveness of prostate cancer testing in Sweden

Amount granted for 2025-2027: SEK 4 500 000

Martin Eklund

Project title: Reduced prostate cancer mortality by improved prognostication and treatment selection

Amount granted for 2025-2027: SEK 4 500 000

Marike Gabrielson

Project title: Compliance and response to tamoxifen therapy in breast cancer - A project in precision medicine and individualised therapy

Amount granted for 2025-2027: SEK 3 000 000

Henrik Grönberg

Project title: ProBio: An outcome-adaptive and randomised multi-arm biomarker driven study in patients with metastatic prostate cancer

Amount granted for 2025-2027: SEK 6 750 000

Maria Hedelin

Project title: Diet during radiation therapy to improve long-term intestinal health among cancer survivors - a placebo-controlled randomized trial (FIDURA)

Amount granted for 2025-2027: SEK 3 000 000

Sara Hägg

Project title: Organ-specific biological aging and risk of different cancers

Amount granted for 2025-2026: SEK 1 600 000

Bojing Liu

Project title: AI-driven Precision Medicine: A Multi-modal Approach to Enhance Cancer Prognosis and Treatment Personalization

Amount granted for 2025-2027: SEK 3 000 000

Anna Plym

Project title: Identifying cancer prevention strategies for men at increased genetic risk for prostate cancer

Amount granted for 2025-2027: SEK 3 000 000

Clinical treatment study grants from the Swedish Cancer Society

Jana de Boniface

Project title: Physical exercise during neoadjuvant chemotherapy for breast cancer as a means to increase pathological complete response rates: the randomized Neo-ACT trial

Amount granted for 2025-2029: SEK 12 000 000

Marike Gabrielson

Project title: The POWER trial: A randomised open label phase 3 clinical trial on Personalised dose Optimization With adjuvant tamoxifen therapy in breast cancER

Amount granted for 2025-2029: SEK 9 000 000

Tobias Nordström

Project title: A randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged ≥75 years with nonmetastatic high-risk prostate cancer (SPCG 19)

Amount granted for 2025-2027: SEK 5 000 000 SEK

FORTE project grants

Isabell Brikell

Project title: Why are psychiatric diagnoses and medication increasing among children and adolescents? An investigation of contributing factors in a nationally representative study of 34,000 young people over 20 years.

Amount granted for 2025-2027: SEK 4 998 000

Shuyang Yao

Project title: Specifying the relationship between substance abuse and schizophrenia, focusing on adolescents and young adults.

Amount granted for 2025-2027: SEK 4 997 000

Grants from the Swedish Research Council

Cynthia Bulik

Project grant

Project title: Defining the role of metabolic, immune, and neurotrophic markers in the etiology of eating disorders through analysis of PKU samples.

Amount granted for 2025-2027: SEK 3 000 000

Zheng Chang

Consolidator grant

Project title: Personalized medication treatment for ADHD (Attention Deficit Hyperactivity Disorder)

Amount granted for 2025-2029: SEK 10 000 000

Grants from the Erling-Perssons Foundation

Kamila Czene

Project title: Enhanced detection of interval breast cancer during screening by combining molecular and imaging-based markers.

Amount granted for 2025-2027: SEK 6 000 000

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.